Is Celcuity Inc. (CELC) a Buy, Sell, or Hold?
NASDAQ : CELC
Celcuity Inc.
$87.64 USD
$4.38 (5.26%)
- Volume
- 1.32M
- Average Volume
- 1.66M
- Market Capitalization
- $4.27B
- P/E Ratio
- -22.53
- Dividend Yield
- 0.00%
- Price Target
- $157.00
- Year High
- $151.02
- Year Low
- $38.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $12.31
Company Overview
NASDAQ
Brian F. Sullivan
Biotechnology
Healthcare
CELC
155
US
USD
Liquidity Metrics
3.65
12.31
12.31
4.37
0.00
Sales & Valuation
-$
0.00
89.18
-24.71
-3.18
Profitability
-$3.78
-$177.04M
0.00%
0.00%
-244.61%
-47.03%
P/E Metrics
-22.53
0.94
0.94
Analyst Price Target & Rating
$157.00
$178.00
$110.00
1/5
12 Analysts
-44.18%
Financial Health Scores
4.83
2/9
$375.72M
$410.16M
$356.64M
-$172.84M
Key Metrics (TTM)
$4.11B
0.00
-23.81
12.31
-244.61%
-49.49%
-4.25%
-4.26%
-81185 days
Company Executives
| Name | Title |
|---|---|
| Brian F. Sullivan | Co-Founder, Chairman & Chief Executive Officer |
| Igor Gorbatchevsky | Chief Medical Officer |
| Jodi Sievers | Head of Investor Relations & Corporate Communications |
| Vicky Hahne | Chief Financial Officer |
| Lance G. Laing | Co-Founder, Chief Science Officer, Vice President, Secretary & Director |
| Sheri Smith | Acting Head of Clinical Operations |
| Eldon C. Mayer | Chief Commercial Officer |
| Brent Eilefson | General Counsel |
Poll Results
No votes yet today — be the first to share your view!
About Celcuity Inc. (NASDAQ:CELC) Stock
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN. ...
2026-07-30 10:00:00
NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Celcuity Inc. ("Celcuity" or the "Company") (NASDAQ: CELC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2026-07-30 08:30:00
REVTORPYK (gedatolisib) in combination with fulvestrant, with or without palbociclib, listed as a preferred Category 1 regimen for second-line or subsequent treatment for tumors without a PIK3CA mutation following progression on or after at least one line of endocrine therapy REVTORPYK (gedatolisib) in combination with fulvestrant, with or without palbociclib, listed as a preferred Category 1 regimen for second-line or subsequent treatment for tumors without a PIK3CA mutation following progression on or after at least one line of endocrine therapy
2026-07-29 10:55:00
RADNOR, Pa., July 29, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Celcuity Inc. (NASDAQ: CELC) on behalf of investors who purchased or acquired Celcuity Inc. securities and experienced significant financial losses.
2026-07-28 19:50:00
RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Celcuity Inc. (NASDAQ: CELC) on behalf of investors who purchased or acquired Celcuity Inc. securities and experienced significant financial losses. Celcuity Announces Unexpected Delayed Drug Launch On July 14, 2026, Celcuity Inc. issued a press release announcing that it had secured F.
2026-07-28 17:31:00
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Celcuity Inc. (“Celcuity” or the “Company”) (NASDAQ: CELC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
2026-07-23 10:00:00
NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Celcuity Inc. ("Celcuity" or the "Company") (NASDAQ: CELC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2026-07-21 16:58:00
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Celcuity (CELC) To Contact Him Directly To Discuss Their Options
Why CELC Stock Declined 15% in a Week Despite a Major FDA Win
2026-07-21 14:31:07
Celcuity slides 15% despite FDA approval of Revtorpyk as investors focus on a late Q3 2026 launch that delays commercial sales and near-term revenues.
Frequently Asked Questions
-
What is the current Celcuity Inc. (CELC) stock price?
-
Celcuity Inc.(NASDAQ:CELC) stock price is $87.64 in the last trading session. During the trading session, CELC stock reached the peak price of $151.02 while $38 was the lowest point it dropped to. The percentage change in CELC stock occurred in the recent session was 5.26% while the dollar amount for the price change in CELC stock was $4.38.
-
CELC's industry and sector of operation?
-
The NASDAQ listed CELC is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CELC?
-
Brian F. Sullivan | Co-Founder, Chairman & Chief Executive Officer
Igor Gorbatchevsky | Chief Medical Officer
Jodi Sievers | Head of Investor Relations & Corporate Communications
Vicky Hahne | Chief Financial Officer
Lance G. Laing | Co-Founder, Chief Science Officer, Vice President, Secretary & Director -
How many employees does CELC have?
-
Number of CELC employees currently stands at 155. CELC operates from 2800 Campus Drive, Minneapolis, MN 55446, US.
-
Link for CELC official website?
-
Official Website of CELC is: https://www.celcuity.com
-
How do I contact CELC?
-
CELC could be contacted at phone #763 392 0767 and can also be accessed through its website. CELC operates from 2800 Campus Drive, Minneapolis, MN 55446, US.
-
How many shares of CELC are traded daily?
-
The average number of CELC shares traded daily for last 3 months was 1.66M.
-
What is the market cap of CELC currently?
-
The market value of CELC currently stands at $4.27B with its latest stock price at $87.64